Biogen asks why Ireland won’t fund new spinal muscular atrophy drug
Biogen is also urgently calling on the HSE to reform the appraisal process for orphan medicines to treat rare diseases, arguing that there is a need for a greater degree of flexibility for these assessments
Biogen Ireland has called on Minister for Health Simon Harris to explain why Ireland joined an EU pharma partnership yet remains the only country in the partnership refusing to fund Biogen’s drug.
Ireland joined the partnership, called BeNeLuxA (Belgium, Netherlands, Luxembourg, Austria) in June. It aims to jointly negotiate pharmaceutical deals.
The partnership recently reached its first collective pricing agreement on Spinraza, which is used to treat Spinal Muscular Atrophy (SMA) – a debilitating,...
Subscribe from just 1€
Choose the subscription that is right for you
For the first month
€19.99 Monthly ThereafterSubscribe today
For the first year
€199.99 annually thereafterSubscribe today
For the first 90 days
€55.00 quarterly ThereafterSubscribe today
These offers are not available for current subscribers. Offers and pricing are subject to change without notice.
Terms & Conditions Apply